|
CA2217373A1
(en)
*
|
1996-10-10 |
1998-04-10 |
Michael John Martin |
Benzo¬b|thiophene compounds, intermediates, formulations, and methods
|
|
US6288105B1
(en)
|
1997-04-30 |
2001-09-11 |
Eli Lilly And Company |
Antithrombotic agents
|
|
JP2002501503A
(ja)
|
1997-04-30 |
2002-01-15 |
イーライ・リリー・アンド・カンパニー |
抗血栓症剤
|
|
JP2001523254A
(ja)
|
1997-04-30 |
2001-11-20 |
イーライ・リリー・アンド・カンパニー |
抗血栓剤
|
|
AU7274098A
(en)
|
1997-04-30 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
AU7274198A
(en)
|
1997-04-30 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
ATE253359T1
(de)
|
1997-05-01 |
2003-11-15 |
Lilly Co Eli |
Antithrombotische mittel
|
|
US7008950B1
(en)
|
1997-06-05 |
2006-03-07 |
Takeda Chemical Industries, Ltd. |
Benzofurans as suppressors of neurodegeneration
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6166069A
(en)
*
|
1998-05-12 |
2000-12-26 |
American Home Products Corporation |
Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
|
PT997460E
(pt)
*
|
1998-10-28 |
2003-03-31 |
Lilly Co Eli |
Compostos benzotiofenos como agentes antitromboticos e seus intermediarios
|
|
DE69914563T2
(de)
|
1998-10-30 |
2004-12-16 |
Eli Lilly And Co., Indianapolis |
Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
|
|
ATE259802T1
(de)
*
|
1999-11-19 |
2004-03-15 |
Lilly Co Eli |
Verbindungen mit antithrombotischer wirkung
|
|
EP1395563B1
(en)
|
2001-05-22 |
2006-03-29 |
Eli Lilly And Company |
2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
|
|
EP1401446B1
(en)
|
2001-05-22 |
2005-02-09 |
Eli Lilly And Company |
Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
|
|
US7998986B2
(en)
|
2001-12-21 |
2011-08-16 |
Exelixis Patent Company Llc |
Modulators of LXR
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
PL374845A1
(en)
*
|
2002-07-22 |
2005-11-14 |
Eli Lilly And Company |
Selective estrogen receptor modulators containing a phenylsulfonyl group
|
|
US7296361B2
(en)
*
|
2003-07-31 |
2007-11-20 |
University Of Pittsburgh |
Measuring device and method of measuring
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
CN104109155A
(zh)
|
2003-08-01 |
2014-10-22 |
田边三菱制药株式会社 |
新颖化合物
|
|
CA2597447C
(en)
|
2005-02-14 |
2014-03-25 |
Bionomics Limited |
Novel tubulin polymerisation inhibitors
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
MX2010002695A
(es)
|
2007-09-10 |
2010-04-01 |
Janssen Pharmaceutica Nv |
Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
WO2011047113A1
(en)
|
2009-10-14 |
2011-04-21 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
NZ703128A
(en)
|
2010-05-11 |
2016-04-29 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
|
|
WO2012140120A1
(en)
|
2011-04-13 |
2012-10-18 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
CA2862981C
(en)
|
2011-12-15 |
2020-02-25 |
Bayer Pharma Aktiengesellschaft |
Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
|
|
CA2865021C
(en)
|
2012-02-23 |
2020-06-30 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
|
KR20170118687A
(ko)
|
2015-02-19 |
2017-10-25 |
제이엔씨 주식회사 |
벤조티오펜을 가지는 액정성 화합물, 액정 조성물 및 액정 표시 소자
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
KR102218333B1
(ko)
|
2016-06-07 |
2021-02-22 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
|
SG11201908820VA
(en)
|
2017-03-23 |
2019-10-30 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
CN112839935A
(zh)
|
2018-09-26 |
2021-05-25 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|